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Abstract
Zeaxanthin is a predominant xanthophyll in human eyes and may reduce the risk of cataracts and age-related macular degeneration.
Spirulina is an algal food that contains a high concentration of zeaxanthin. In order to determine the zeaxanthin bioavailability of spirulina
for dietary supplementation in humans, spirulina was grown in nutrient solution with 2H2O for carotenoid labelling. Single servings of
2H-labelled spirulina (4·0–5·0 g) containing 2·6–3·7 mg zeaxanthin were consumed by fourteen healthy male volunteers (four Americans
and ten Chinese) with 12 g dietary fat. Blood samples were collected over a 45 d period. The serum concentrations of total zeaxanthin were
measured using HPLC, and the enrichment of labelled zeaxanthin was determined using LC-atmospheric pressure chemical ionisation-MS
(LC-APCI-MS). The results showed that intrinsically labelled spirulina zeaxanthin in the circulation was detected at levels as low as 10 % of
the total zeaxanthin for up to 45 d after intake of the algae. A single dose of spirulina can increase mean serum zeaxanthin concentration
in humans from 0·06 to 0·15mmol/l, as shown in our study involving American and Chinese volunteers. The average 15 d area under
the serum zeaxanthin response curve to the single dose of spirulina was 293 nmol £ d/mmol (range 254–335) in American subjects,
and 197 nmol £ d/mmol (range 154–285) in Chinese subjects. It is concluded that the relative bioavailability of spirulina zeaxanthin can
be studied with high sensitivity and specificity using 2H labelling and LC-APCI-MS methodology. Spirulina can serve as a rich source of
dietary zeaxanthin in humans.
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Zeaxanthin and its structural isomer lutein are the most
prevalent xanthophylls found in the human body. They are
highly concentrated in the retina of human eyes. Zeaxanthin
is the major component in the central macula, while lutein is
predominant in the peripheral area(1,2). It is believed that
zeaxanthin and lutein function as blue-light filters and reactive
oxygen species scavengers in the retina to protect the cells
from oxidative damage(3,4).
Numerous studies have suggested that zeaxanthin and
lutein are crucial for visual health. In animal models (in mon-
keys), zeaxanthin and lutein have been found to be important
for the development and maintenance of normal distribution
of the retinal pigment epithelium(5,6); retinal zeaxanthin has
also been shown to protect the photoreceptors from
light-induced damage in quail eyes(7,8). In human subjects,
some epidemiological and clinical researchers have demon-
strated that high levels of zeaxanthin and lutein intake are
associated with significantly decreased risks of cataract and
age-related macular degeneration(9–11).
Because humans cannot synthesise xanthophylls, dietary
intake of xanthophyll-containing foods is critical to provide
these phytonutrients to our bodies. In the US population,
the average intake of lutein and zeaxanthin together is
about 2 mg/d(12), which is three times less than the dose of
lutein and zeaxanthin that has been linked with a decreased
risk of age-related macular degeneration and cataracts
*Corresponding author: Dr G. Tang, fax þ1 617 556 3344, email guangwen.tang@tufts.edu
Abbreviations: AUC, area under the curve; MeOH, methanol; MTBE, methyl tert-butyl diethyl ether; LC-APCI-MS, LC-atmospheric pressure chemical
ionisation-MS.
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(6 mg/d)(11). Therefore, lutein and zeaxanthin supplements
have been suggested for visual health in people with low
dietary intake, especially for older adults.
However, although lutein is abundant in many green
leafy vegetables such as kale and spinach, only a few kinds
of food contain high concentrations of zeaxanthin(13,14). In
cooked egg-yolk, maize and orange pepper, zeaxanthin
concentrations are about 587, 202 and 1665mg/100 g fresh
weight, respectively(13). Spirulina is an alga that is rich in
carotenoids, including zeaxanthin(15–18). In the strain of
spirulina studied in the present investigation, the concen-
tration of zeaxanthin as a dried powder can reach 74 000mg/
100 g(19). Previous studies in animal models as well as in
human subjects have demonstrated that b-carotene from
spirulina has a high bioavailability and a high bioconversion
to vitamin A factor(19); however, no studies on spirulina
zeaxanthin have been reported.
In the present report, the enrichment of spirulina zeax-
anthin in serum and its bioavailability in humans have been
determined. A single serving of intrinsically 2H-labelled spiru-
lina was consumed by American and Chinese healthy males.
Their plasma samples were collected up to 45 d post- spirulina
supplementation. The concentration and isotopic enrichment
of spirulina zeaxanthin were analysed using C30 column-
based HPLC and LC-atmospheric pressure chemical ionis-
ation-MS (LC-APCI-MS). The results were used to calculate a
relative bioavailability (the change in plasma concentration
in response to a test meal)(20), which demonstrated that spiru-
lina is a rich source of dietary zeaxanthin in both American
and Chinese volunteers.
Materials and methods
Subjects and study design
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the Institutional
Review Board of Tufts Medical Center and the Institute of
Nutrition and Food Hygiene Ethical Review Committee of
the Chinese Academy of Preventative Medicine. Informed con-
sent was obtained from all subjects under the guidelines
established.
The human studies were conducted in China and the USA in
2006 and 2008, respectively. For this study, four American
males (two African Americans and two Caucasians) and ten
Chinese males were recruited separately. The volunteers
were healthy, non-smoking adults and were not taking vita-
min supplements at the time of the study. All subjects were
instructed to eat a low-carotenoid diet for 2 weeks before
taking the study dose. On day 1, each subject was given a spir-
ulina supplement of 4 g (for American volunteers) or 5 g (for
Chinese volunteers) with a carotene-free liquid formulated
breakfast. The ingredients of this liquid breakfast contained
banana, coconut milk, whey protein, glucose polymer,
white sugar and water, which provided 12 g fat (26 % of
total energy), 4 g protein (4 % of total energy) and 74 g
carbohydrate (70 % of total energy), with a total energy con-
tent of 1668 kJ (399 kcal).
Fasting blood samples (10 ml) were collected from all sub-
jects before supplementation as the baseline. Blood samples
(10 ml) were collected from all subjects at 0 (fasting blood,
just before breakfast), and 6, 8, 11 and 13 h after intake of
the supplement on day 1. Blood was drawn at 0, 5 and 11 h
on day 2, and at 0 and 11 h on day 3. Fasting blood samples
(10 ml) were obtained on days 4, 5, 6, 7, 11, 13, 15, 19, 23,
27, 32, 39 and 45. Due to the schedules of the volunteers,
time points varied slightly (^1 d) for some subjects and
two subjects had a shorter period of intervention (a minimum
of 23 d).
Chemicals and materials
Most of the solvents used in this study including chloroform,
methanol (MeOH), hexane, ethanol, tert-butyl methyl diethyl
ether (MTBE), tetrahydrofurane were HPLC-grade and pur-
chased from Sigma (St Louis, MO, USA). Diethyl ether was
from Fisher Scientific (Fair Lawn, NJ, USA). NH2 cartridge
columns were from Phenomenex (Torrance, CA, USA).
Preparation of 2H labelled spirulina
2H labelled spirulina (Spirulina platensis) was grown in liquid
culture at the US Department of Agriculture Agricultural
Research Service, Children’s Nutrition Research Center in
Houston, TX, USA as previously described(19). Briefly, a
liquid stock culture of spirulina cells was obtained from the
University of Texas Culture Collection of Algae (UTEX no.
LB2340; University of Texas, Austin, TX, USA), inoculated
into 20-litre glass carboys, and grown in a sterilised artificial
seawater medium enriched with 23 atom % 2H2O. After
10–12 d of growth, the spirulina cultures were harvested,
freeze-dried and shipped to the Carotenoids and Health
Laboratory of the US Department of Agriculture Human Nutri-
tion Research Center on Aging at Tufts University (Boston,
MA, USA), where the freeze-dried spirulina was powdered,
packed into capsules and stored at 2808C immediately.
Spirulina capsules for the China study were shipped by air,
on dry ice, to the National Institute for Nutrition and
Food Safety, Beijing, China. All spirulina capsules were
stored at 2808C until being analysed or consumed by the
study subjects.
Sample preparation
Whole blood samples were protected from light using
aluminium foil, incubated at 378C for 30 min, and centrifuged
at 48C, 800 g for 15 min to separate the serum. Serum samples
collected from Chinese subjects were stored at 2208C first
(less than 2 months) and then shipped by air, on dry ice,
to the Carotenoids and Health Laboratory of HNRCA in
Boston, MA, USA, where the samples were stored at 2808C
until analysis. Due to the light sensitivity of carotenoids, the
extractions and analyses of carotenoids were performed
under red light.
B. Yu et al.2
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To extract carotenoids from spirulina, 1·0 mg of dried
spirulina powder was mixed with 10 ml MeOH for 1 h in a
shaking incubator at 120 rpm. The mixture was centri-
fuged at 3000 rpm for 5 min, and the MeOH extract was
transferred into a 50 ml volumetric flask. The residue was
further extracted with 10 ml of tetrahydrofurane, vortexed
and centrifuged at 3000 rpm for 5 min. Extraction of tetra-
hydrofurane was repeated three or four times, and all
tetrahydrofurane extracts were combined with the MeOH
extract in the same flask. The final volume of the spirulina
extract was adjusted to exactly 50 ml in the volumetric
flask, and 1 ml of the extract was transferred to a 10 ml glass
tube, dried under N2 and resuspended with 1 ml of ethanol
for HPLC and LC-APCI-MS analyses.
To extract carotenoids from human serum, 500ml serum
samples, 500ml of 0·85 % saline, 60ml internal standard (echi-
nenone in ethanol with absorbance of 0·1–0·2 measured at
460 nm), and 5 ml CHCl3–MeOH (2:1, v/v) were added into
15 ml disposable glass tubes. The mixture was vortexed, cen-
trifuged at 3000 rpm for 5 min, and the lower layer was
removed to another 15 ml tube. After removal of the chloro-
form layer, 3 ml hexane and 1 ml ethanol were added to the
remaining aqueous phase, vortexed and centrifuged again.
The upper layer was combined with the CHCl3–MeOH
extract. All samples were extracted in duplicates, and their
chloroform and hexane layers were combined together,
dried under N2 and finally resuspended in 120ml ethanol to
make ready for HPLC analysis.
For LC-APCI-MS analysis, serum was extracted as done
previously, but the final dried residue was resuspended
with 100ml of CHCl3. The CHCl3 solution was added to
the centre of an aminopropyl column (500 mg/3 ml) in the
Vac Elut apparatus, which was conditioned with 2 ml of
hexane. An additional 100ml of CHCl3 was used to wash
the glass tube, and also transferred to the column. Under
a gentle vacuum, the column containing the serum extracts
was washed with 3 ml of hexane once, and eluted with
3 ml of diethyl ether with 3 % acetic acid. The elution
was collected in a 5 ml glass tube, dried under N2 and
resuspended with 120ml of ethanol to make ready for LC-
APCI-MS analysis.
HPLC analysis
The concentrations of xanthophylls in spirulina and human
serum were analysed using a Waters HPLC coupled with
a Waters 994 Programmable Photodiode Array Detector
(Waters Corporation, Milford, MA, USA) and a semi-micro
bore C30 column (3mm, 150 mm £ 3·0 mm; YMC, Wilmington,
NC, USA). The HPLC mobile phase A contained MeOH, MTBE
and 1·5 % ammonium acetate in water (85:12:3, by vol.); and
phase B contained methanol, MTBE and 1·0 % ammonium
acetate in water (8:90:2, by vol.). The gradient procedure,
at a flow rate of 0·4 ml/min, was as follows: 0 % B isocratic
(0–3 min), 0 % B – 20 % B linear gradient (3–10 min), 20 %
B – 55 % B linear gradient (10–18 min), 55 % B – 95 % B
linear gradient (18–33 min), 95 % B – 0 % B linear gradient
(33–37 min), 0 % B isocratic (37–40 min). The total run time
was 40 min and the injection volume was 20ml. The UV–Vis
spectra of all carotenoids were recorded in the range of
250–600 nm, and peak identification was based on compari-
sons with the retention times and absorption spectra of
known carotenoid standards in our laboratory. Data acqui-
sition and processing were performed using Empower Pro
software (version 2.0; Waters Corporation).
LC-atmospheric pressure chemical ionisation-MS analysis
Analysis of zeaxanthin enrichment was performed with an
Agilent LC-MS (Agilent Technologies, Santa Clara, CA, USA)
equipped with an Agilent HPLC, autosampler, UV detector,
HP1100MSD with APCI interface and a C30 column (3mm,
150 mm £ 4·6 mm, Bischoff Chromatography, Leonberg,
Germany). The HPLC mobile phase A contained MeOH,
MTBE and 1·5 % ammonium acetate in water (83:15:2, by
vol.); and phase B contained MeOH, MTBE and 1·0 %
ammonium acetate in water (8:90:2, by vol.). Gradient pro-
cedures (flow rate 1 ml/min) were changed as follows: 0 % B
isocratic (0–2 min), 0 % B – 5 % B linear gradient (2–10 min),
5 % B – 55 % B linear gradient (10–18 min), 55 % B – 95 % B
linear gradient (18–20 min), 95 % B – 0 % B linear gradient
(20–21 min), 0 % B isocratic (21–40 min). The total run time
was 40 min and the injection volume was 60ml. The UV–Vis
spectra of peaks were recorded in the range of 250–600 nm
and the mass spectra were recorded using the following
parameters: polarity, positive; mass range, m/z 550–590;
fragmentor, 90; gain, 20·00; threshold, 150; and stepsize, 0·1.
Data acquisition and process were performed using Chem-
Stations software (Agilent Technologies).
Data process and statistical analysis
The enrichment of labelled zeaxanthin was calculated by
integrating the areas of labelled and unlabelled zeaxanthin
in extracted ion chromatographs and by using the following
equations (1–3):
X
Unlabelled zeaxanthin ¼
X
areas of m=z 5692571: ð1Þ
X
Labelled zeaxanthin ¼
X
areas of m=z 5732583: ð2Þ
Enrichmentof labelled zeaxanthinfromspirulina ð%Þ
¼
X
labelled zeaxanthin£100
 
=
X
labelled zeaxanthin

þ
X
unlabelled zeaxanthin

:
ð3Þ
The serum response of labelled zeaxanthin was calculated
using equation 4, in which 0·0435 is the serum volume in
litres/kg of body weight:
Serum response of labelled zeaxanthin ðnmolÞ
¼ enrichment of labelled zeaxanthin in total zeaxanthin
£ total serum zeaxanthin concentration
£ body weight ðin kgÞ £ 0:0435: ð4Þ
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The area under the curve (AUC) of labelled zeaxanthin was
calculated by using the curve of serum response of labelled
zeaxanthin (nmol, as y axis) v. time (day, as x axis) via
Integral-curve of Kaleidagraph software (version 3.5; Synergy
Software, Reading, PA, USA). For all subjects, the AUC
up to 15 d (AUC0–15 d) was calculated directly or calculated
proportionally between the two nearest time points.
The average response to labelled spirulina zeaxanthin in
the circulation was calculated using equation 5:
Average serum response to labelled spirulina zeaxanthin
ðnmol £ d=mmolÞ ¼ AUC0215 d of labelled
spirulina zeaxanthin=consumed zeaxanthin dose ðmmolÞ:
ð5Þ
All statistical analyses were performed using Graphpad
Prism for Windows software (version 4.0; GraphPad Software,
San Diego, CA, USA). An unpaired t test was used to assess the
significance of differences of age, body weight, BMI values,
baseline concentrations of xanthophylls and serum responses
to labelled spirulina zeaxanthin between American and
Chinese subjects.
Results
Characteristics of American and Chinese subjects
As previously mentioned, two groups of middle-aged, healthy,
non-smoking males were recruited in the USA (n 4) and China
(n 10), respectively. The age range of American subjects is
46–52 (49·3 (SD 2·8)) years; weight range is 68·9–83·5 (76·3
(SD 6·1) kg); and BMI range is 23·1–26·5 (25·5 (SD 1·6)) kg/m2.
The age range of Chinese subjects is 41–57 (48·1 (SD 5·7)) years;
weight range is 52·2–78·4 (66·7 (SD 8·1)) kg; and BMI range
is 17·9–27·4 (23·4 (SD 3·1)) kg/m2. Although the mean
values of age, body weight and BMI of American subjects
were higher than those of Chinese subjects, there were no
statistically significant differences between them for these
characteristics.
The carotenoid concentrations of all subjects in the two
groups were in the reported ranges(21) (data not shown).
The range of lutein concentrations was 0·12–0·18mmol/l in
the American group and 0·27–0·52mmol/l in the Chinese
group, while the range of zeaxanthin concentrations was
0·04–0·07 and 0·05–0·09mmol/l in the American and Chinese
groups, respectively.
Quantification of 2H-labelled zeaxanthin in spirulina
HPLC analyses showed that in the spirulina produced for
this study, trans-zeaxanthin and trans-b-carotene were the
two major carotenoids and cryptoxanthin, 13-cis-b-carotene
and 9-cis-b-carotene were also present in low concentrations
(Fig. 1). There was no lutein contained in the spirulina that
we studied, and echinenone was too small to affect the
experiment (Fig. 1).
Due to the different times at which the human studies
were conducted in the USA (2008) and China (2006), the
2H-labelled spirulina was harvested in different batches.
The concentration of spirulina zeaxanthin was 0·66 mg/g in
the batch for American volunteers and 0·74 mg/g for Chinese
volunteers; therefore, the dose of labelled spirulina zeaxanthin
was 2·63 mg (4·61mmol) for American volunteers and 3·68 mg
(6·46mmol) for Chinese volunteers (Table 1).
Using LC-APCI-MS, the most abundant protonated mole-
cules of unlabelled zeaxanthin were identified at m/z 569
(zeaxanthin þ Hþ), and ions of anhydrozeaxanthin at m/z
551 (zeaxanthin þ Hþ 2 H2O) with an abundance of 12·6 %
(Fig. 2(a)). About 99 % of zeaxanthin in the labelled
spirulina was enriched with 2H, and Gaussian distribution
of isotopomers of zeaxanthin had the most abundant
5·0
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Fig. 1. Separation of carotenoids from 2H-labelled spirulina in this study
by HPLC analysis. Peaks were identified as: (1) trans-zeaxanthin; (2)
chlorophyll; (3) cryptoxanthin; (4) 13-cis-b-carotene; (5) all-trans-b-carotene;
(6) 9-cis-b-carotene.
Table 1. Baseline concentrations of serum lutein and zeaxanthin, and serum response to labelled spirulina zeaxanthin in American and Chinese subjects
(Ranges, mean values and standard deviations)
Subjects. . . American Chinese
Range Mean SD Range Mean SD
Batch of spirulina (year) 2008 2006
Dosage of zeaxanthin (mg) 2·63 3·68
Baseline concentration of serum lutein (mmol/l)* 0·12–0·18 0·16 0·03 0·27–0·52 0·39 0·09
Baseline concentration of serum zeaxanthin (mmol/l)* 0·04–0·07 0·06 0·01 0·05–0·09 0·07 0·01
Concentration of serum zeaxanthin 1 d post-supplementation (mmol/l) 0·09–0·14 0·11 0·02 0·11–0·24 0·15 0·04
Highest value of labelled zeaxanthin as percentage of total zeaxanthin (%) 59–65 62 NS 43–56 49 NS
AUC of labelled zeaxanthin (nmol £ d)† 1167–1542 1346 153 998–1851 1279 293
Average serum response (nmol £ d/mmol)‡ 254–335 293 33 154–285 197 45
AUC, area under the curve.
* Baseline concentration was measured 4 d before the supplementation of spirulina.
† AUC was measured over 15 d for all subjects.
‡ Average serum response is the 15 d area under the labelled zeaxanthin response curve per mmol of consumed spirulina zeaxanthin.
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enrichment of 8 2H at m/z 577 (zeaxanthin þ 2H8 þ Hþ;
Fig. 2(b)). Similar isotopomer distribution of anhydrozeaxanthin
ions (zeaxanthin þ 2H8 þ Hþ 2 H2O, zeaxanthin þ2H8 þ Hþ
22H2O) at m/z 559 and m/z 541 were also observed, with the
abundance of 15·1 and 7·5%, respectively (Fig. 2(b)).
Enrichment of labelled spirulina zeaxanthin in circulation
in human subjects
The representative HPLC chromatographs and mass spectra of
human serum zeaxanthin (from American subject 2) before
and 48 h after supplementation with spirulina are shown in
Fig. 3. The HPLC chromatographs demonstrate that serum
extracts before and after supplementation shared similar caro-
tenoid profiles (Fig. 3). All trans-lutein eluted at 6·9 min,
and all trans-zeaxanthin eluted at 8·5 min. The amount of
lutein decreased slightly 48 h post-supplementation (Fig. 3(a),
before supplementation), but the amount of zeaxanthin
greatly increased 48 h post-supplementation (Fig. 3(a), after
supplementation).
According to the distribution of zeaxanthin mass (Fig. 2),
the peaks of m/z 569–571 were assigned as endogenous
unlabelled zeaxanthin, while those of m/z 573–583 were
assigned as the 2H-labelled zeaxanthin from spirulina.
Extracted ion chromatographs of unlabelled and labelled
zeaxanthin showed that, before the supplementation, no
labelled zeaxanthin was detectable at 8·5 min (Fig. 3(b),
before supplementation); however, 48 h after supplemen-
tation, both labelled and unlabelled zeaxanthin were present
(Fig. 3(b), after supplementation). The Gaussian isotopomer
distribution of 2H-labelled zeaxanthin was clearly visible after
supplementation (Fig. 3(c), after supplementation), but not
before supplementation (Fig. 3(c), before supplementation),
in the mass spectrum of the zeaxanthin peak maximum.
Serum responses to labelled spirulina zeaxanthin in
American and Chinese volunteers
Although we followed the labelled zeaxanthin trace in the
circulation up to 45 d, only data over 21 d are presented in
the graphs. The concentrations of serum zeaxanthin increased
dramatically about 1–2 d post-supplementation in all subjects
(data not shown). The mean value of serum zeaxanthin con-
centration 1 d after supplementation increased from baseline
of 0·06 to 0·11mmol/l in American subjects and from
baseline of 0·07 to 0·15mmol/l in Chinese subjects (Table 1).
Over the 21 d of this study, the serum concentrations of total
zeaxanthin fluctuated in some subjects (e.g. American subject
1 and Chinese subject 7), but were relatively stable in others
(e.g. American subject 2 and Chinese subject 10; Fig. 4).
In all subjects, the enrichment of labelled zeaxanthin in the
circulation reached a maximum between 1 and 3 d post-
supplementation, and then decreased with little variation
(Fig. 5 and data not shown). The amount of serum labelled
zeaxanthin followed a similar pattern (Fig. 5). The mean
highest value of labelled zeaxanthin as percentage of total
zeaxanthin in American subjects was 62 % (range 59–65 %),
and was 49 % in Chinese subjects (range 43–56 %; Table 1).
Area under the curve of labelled spirulina zeaxanthin
responses in American and Chinese subjects
The AUC of labelled zeaxanthin was integrated using
amounts of labelled zeaxanthin v. time over 15 d due to
the detectability of the zeaxanthin. American subjects had
a mean value of 1346 nmol £ d and Chinese subjects had a
mean value of 1279 nmol £ d (Table 1). The mean value of
the average serum response, which is the 15 d area under the
serum labelled zeaxanthin response curve (in nmol £ d) divided
by the consumed zeaxanthin dose (in mmol), was 293 nmol
£d/mmol in American subjects (range 254–335), and was
197 nmol £ d/mmol in Chinese subjects (range 154–285).
Discussion
In the present study, we utilised 2H labelling and LC-APCI-MS
to determine the bioavailability of spirulina zeaxanthin in
human subjects. The peaks of enrichment of (M þ 2H8) and
measurable isotopomers from (M þ 2H1) through (M þ 2H14)
of labelled zeaxanthin were easily discernible from unlabelled
zeaxanthin in human serum extracts (Fig. 3). After the
study, subjects took a single dose of spirulina, and the labelled
zeaxanthin was detected as early as 1 d post-supplementation
100
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Fig. 2. Mass spectra of unlabelled and labelled zeaxanthin analysed by
LC-atmospheric pressure chemical ionisation-MS. (a) Molecular mass of
unlabelled zeaxanthin standard; (b) isotopomer distribution of zeaxanthin
fraction from 2H-labelled spirulina.
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Fig. 3. LC-atmospheric pressure chemical ionisation-MS analysis of serum extracts (American subject 2) before and after supplementation with 2H-labelled spiru-
lina. (a) HPLC separation of the carotenoids in the serum. (b) Extracted ion chromatograms (EIC) of unlabelled (m/z 569–571, ) and labelled (m/z 573–583,
) zeaxanthin. , UV450. (c) Mass spectra at the peak maximum of zeaxanthin before and 48 h after supplementation with 2H-labelled spirulina.
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(Fig. 5), and enrichments could be measured in circulation up
to 45 d post-feeding (data not shown). Therefore, the serum
response to labelled zeaxanthin from spirulina was sensitively
detected with minimal influences by their daily dietary intake
of zeaxanthin.
Our present study showed that spirulina is a good dietary
source of zeaxanthin which can effectively increase serum
zeaxanthin concentration in humans. There are several studies
reporting the influence of dietary zeaxanthin on subject
plasma zeaxanthin concentrations(22–26). In one study with
older adults, egg-yolk supplementation of a beef tallow diet
or a maize oil diet increased plasma zeaxanthin concen-
trations by 142 or 114 %, respectively(26). A similar study of
a 12-week egg intervention also showed that egg intake sig-
nificantly increased serum zeaxanthin concentrations in
women(22). In a recently reported study, consumption of
four egg-yolks/d for 5 weeks in older adults increased
serum zeaxanthin concentrations from 0·03 to 0·06mmol/l(23).
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Fig. 4. Serum concentrations of total zeaxanthin (in mmol/l) after supplementation with spirulina over 21 d in representative subjects (American subjects 1, 2 and
Chinese subjects 7, 10).
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In our study, a single dose of 4·0 or 5·0 g spirulina significantly
increased the zeaxanthin concentrations in the circulation of
both American and Chinese subjects. One day after supple-
mentation, the mean concentration of total serum zeaxanthin
increased from 0·06 to 0·11mmol/l in American subjects
(2·63 mg zeaxanthin dose) and from 0·07 to 0·15mmol/l in
Chinese subjects (3·68 mg zeaxanthin dose; Table 1). Because
egg-yolks contain a substantial amount of cholesterol,
spirulina could be a good, alternative source of zeaxanthin
for those individuals seeking to limit their dietary cholesterol
intake. Consumption of vegetables such as spinach and
maize at dietary levels have been reported to result in no
increases in plasma zeaxanthin concentrations(25).
There are several factors that might be contributing to
the high bioavailability of spirulina zeaxanthin in humans.
First, dried spirulina powder contains an extremely high
concentration of zeaxanthin, about 50–300 times higher than
that in cooked egg-yolk, maize or pepper(13). In the present
study, a single dose of 2·6 or 3·7 mg zeaxanthin was admini-
strated to subjects, which might be difficult to achieve if
other diets are chosen. Second, the spirulina cell wall is com-
posed of proteins and peptidoglycans that can be digested
easily, which helps zeaxanthin to be released from the food
matrix(14,16). In addition, spirulina contains high concen-
trations of NEFA that can reach 9–14 % of the dry weight of
spirulina(16,27–29). Since fat can increase the bioavailability
of carotenoid absorption(22,23), the lipid matrix contained in
spirulina may facilitate the absorption of zeaxanthin.
We observed a significant difference of average serum
response to a single dose of spirulina zeaxanthin in middle-
aged American and Chinese males (Table 1). However, it
should be noted that the difference we observed was from
two small groups (four American subjects, ten Chinese sub-
jects), and no conclusion on racial differences of zeaxanthin
absorption could be made at this point. Since it is known
that both age and sex may affect the serum response to caro-
tenoids(30–32), the substantial response to spirulina zeaxanthin
should be further investigated in other populations. With
the present study, our data strongly suggested that spirulina
is a rich dietary zeaxanthin source, which might benefit the
general population for visual health.
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